BART service between Berkeley, Richmond halted due to medical emergency
BART service between the Berkeley and Richmond stations Friday morning has been halted due to a medical emergency, officials said.
Around 6:50 a.m., the agency announced on social media that service was stopped following reports of a "major medical emergency" outside of the North Berkeley station. Additional details about the emergency were not immediately available.
BART service has stopped between Downtown Berkeley and Richmond stations due to a major medical emergency outside of North Berkeley station. AC Transit is providing bus service between Richmond and Berkeley stations. — BART Alert (@SFBARTalert) June 13, 2025
BART said AC Transit is providing bus service between Richmond and Berkeley stations.
Friday's incident is the second service disruption due to a medical emergency in as many days. On Thursday morning, an emergency at the Hayward station halted service for two hours between Bayfair and the South Hayward stations.
This is a breaking news update. More details to come.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
5 hours ago
- Washington Post
Solution to Evan Birnholz's June 22 crossword, ‘What Keeps Me Up at Night'
I've had bad sleep habits since I was a child. I pulled my first all-nighter at age 12, when I frantically tried to finish a work of short fiction for a school writing contest. Ever since then I've been a night owl, staying up well past any reasonable hour virtually every week to finish assignments in high school and college and graduate school, or crosswords in my professional life now, or sometimes for no good reason at all (once you fall into a YouTube rabbit hole, it can be hard to climb out). For the past three decades, a night where I went to bed before 2 a.m. has been the exception rather than the norm.
Yahoo
14 hours ago
- Yahoo
Delaware governor signs executive order protecting gender-affirming care
On Friday, Delaware Democratic Gov. Matt Meyer signed an executive order increasing protection for receivers and providers of gender-affirming care. 'In Delaware, we cherish privacy, dignity and the right to make personal medical decisions. Everyone deserves the freedom to access healthcare rooted in science and compassion,' said Meyer. The executive order prohibits any state agency from providing 'medical records, data or billing information, or utilize state resources' that could help any criminal or civil investigation against someone receiving or providing gender-affirming care. It also dictated that the state professional regulations board cannot disbar healthcare professionals only due to providing gender-affirming care. California, New York, Illinois and 11 other states, and Washington, D.C., have enacted similar legislation to shield patients and doctors from aggressive legislation in states where gender-affirming care is highly restricted. Patients can now travel to shield states to receive their care without fear of retribution in their home states. This comes after a Supreme Court decision on June 18 that upheld Tennessee's decision to ban puberty blockers and hormone treatments for transgender minors. 'This ruling undermines doctors in delivering care to some of the most vulnerable patients in our country,' Rep. Sarah McBride (D-Del.), the nation's first openly transgender member of Congress, said Wednesday on the social platform X. Since President Trump took office transgender rights have increasingly been limited. Trump signed an executive order recognizing only two genders, has tried to ban transgender troops from the military, has refused requests to change the gender of passports and has tried to defund gender-affirming medical care. Delaware has a long history of tolerance for LGBTQ populations. According to the order, the state hosts 40,000 LGBTQ individuals and 6,300 transgender adults. In 2013, it legalized same-sex marriage and implemented anti-discrimination laws in housing, employment and public accommodation. 'We will do everything in our power to protect transgender families in the state of Delaware and throughout the country,' the Executive Committee of the Delaware Democratic Party PRIDE Caucus said in a press statement earlier this week. 'We call on every legislator, from the state and county level to the federal level, to speak out and step up. This is the moment to act – not with caution, but with courage.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
17 hours ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
